Prestige Consumer Healthcare Inc. (PBH) - 10-Q Summary
Business Context and Reporting Period
Prestige Consumer Healthcare Inc. is a developer, manufacturer, and distributor of over-the-counter (OTC) health and personal care products. This report covers the first quarter of fiscal year 2027, ended June 30, 2026. The quarter was defined by significant M&A activity, specifically the acquisition of the "OTC Wellness Business" (including the Breathe Right brand) on June 12, 2026, for $1.045 billion.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenues | $265.7 million | $249.5 million | +6.5% |
| Gross Profit | $136.2 million | $140.3 million | -3.0% |
| Gross Margin | 51.3% | 56.2% | -490 bps |
| Operating Income | $52.5 million | $71.8 million | -26.8% |
| Net Income | $29.2 million | $47.5 million | -38.5% |
| Diluted EPS | $0.61 | $0.95 | -35.8% |
| Operating Cash Flow | $70.8 million | $79.0 million | -10.4% |
| Free Cash Flow | ($1,056.9 million) | $78.2 million | N/A |
| Total Debt (Gross) | $2.045 billion | $1.000 billion | +104.5% |
| Cash & Equivalents | $89.1 million | $139.5 million | -36.1% |
Note: Free Cash Flow is calculated as Operating Cash Flow less Capital Expenditures ($3.7M) and Acquisitions ($1.045B).
Material Changes vs. Prior Period
- Revenue Growth: Driven by the acquisition of the OTC Wellness Business (Breathe Right) and organic growth in Gastrointestinal and Dermatological categories. The new "Wellness, Sleep & Other" category grew 165.7% year-over-year.
- Margin Compression: Gross margin declined to 51.3% from 56.2%. This was primarily due to the amortization of inventory fair value step-up from the OTC Wellness acquisition and costs to optimize the newly acquired Pillar5 manufacturing facility.
- Expense Increases: General and Administrative (G&A) expenses surged $14.8 million to $43.3 million, largely due to $10.6 million in acquisition-related transaction costs. Interest expense increased to $13.9 million from $10.2 million due to the new $1.045 billion term loan.
- Balance Sheet Shift: Total debt doubled to $2.045 billion to fund the Breathe Right acquisition. Intangible assets increased by $948.4 million and Goodwill by $65.5 million related to the acquisition.
Outlook, Risks, and Unusual Items
- Acquisition Integration: The company is integrating the OTC Wellness Business and the previously acquired Pillar5 Pharma. Pro forma results for Q1 2026 (assuming the acquisition occurred at the start of the prior year) would have shown revenues of $297.5 million and net income of $36.4 million.
- Supply Chain Risks: Management highlighted ongoing shortages in sterile eye care products due to regulatory scrutiny and manufacturing constraints at third-party suppliers. This has negatively impacted sales in the Eye & Ear Care category.
- Subsequent Events:
- LaCorium Health Acquisition: Completed on July 1, 2026, for ~$150 million, funded by an additional $95 million draw on the term loan.
- Debt Refinancing: On July 15, 2026, the company issued $400 million of 6.25% Senior Notes due 2034 to redeem the 5.125% 2019 Senior Notes.
- Economic Environment: Risks include inflation, supply chain constraints, and geopolitical events affecting input costs and consumer demand.
Investor Verification Checklist
- Acquisition Synergies: Verify the timeline and magnitude of cost synergies expected from the Breathe Right and LaCorium Health acquisitions to offset the immediate margin pressure.
- Eye Care Supply Chain: Monitor updates on the resolution of sterile eye care manufacturing shortages and their impact on the Eye & Ear Care revenue stream.
- Debt Service Capacity: Assess the impact of the increased interest expense (average cost of borrowing rose to 5.1%) and the new 6.25% senior notes on future cash flow and covenant compliance.
- Amortization Impact: Confirm the duration and magnitude of the non-cash amortization charges related to the $948 million in acquired intangible assets.
- Customer Concentration: Note that Walmart and Amazon accounted for 19% and 16% of gross revenues, respectively; monitor any shifts in retailer purchasing patterns.